Ascentage Pharma reported 2024 sales of $134.3M, up 342% YoY, driven by a $100M option payment from Takeda under an exclusive agreement. JP Morgan initiated Ascentage Pharma with an Overweight rating ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $21.89 ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as Vyjuvek gains traction in the U.S. market. In the year-ago quarter, the ...

Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today ...

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year. Aided by a rebound in ...